Sustained-Release Liothyronine Capsule Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current T3 hormone replacement therapies for hypothyroidism suffer from fluctuating serum levels due to immediate-release formulations, leading to inconsistent treatment and adverse effects, as they do not maintain stable concentrations, failing to address individual patient needs effectively.
Innovation Solution
Development of sustained-release oral capsule formulations containing liothyronine or its salt, hydroxypropyl methylcellulose, and a filler, which exhibit a Zero order or Higuchi release kinetic pattern, providing prolonged drug release and more consistent plasma levels, allowing for customized dosage forms to achieve targeted serum levels of T3 and T4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate-release T3 formulations are used, then rapid absorption and high bioavailability are achieved, but serum T3 levels fluctuate and treatment consistency deteriorates
Solution Approach 1:
The patent changes the release rate parameter of T3 by using sustained-release technology with controlled-release matrices (hydroxypropyl methylcellulose, ethylcellulose, or wax coatings) to transform the rapid absorption characteristic into a controlled, sustained release profile, thereby stabilizing serum T3 levels while maintaining adequate absorption
Solution Approach 2:
The sustained-release formulation ensures continuous delivery of T3 over an extended period (12-24 hours), replacing the intermittent peak-trough pattern of immediate-release formulations with a continuous therapeutic action that maintains stable serum concentrations
2Reliability
If immediate-release T3 formulations are administered multiple times daily, then adequate T3 levels are maintained, but treatment complexity and dosing frequency increase
Solution Approach 1:
The patent transforms the static dosing regimen (fixed multiple daily doses) into a dynamic sustained-release system that automatically adjusts drug delivery over time, allowing once-daily or twice-daily administration while maintaining reliable therapeutic levels through the formulation's inherent release characteristics
3Reliability
If higher T3 dosages are used to treat resistant patients, then therapeutic effectiveness may improve, but adverse effects and over-treatment risk increase
Solution Approach 1:
The sustained-release formulation changes the concentration-time profile parameter from peak-intensive to sustained-low-level delivery, providing adequate therapeutic exposure over time while avoiding the high peak concentrations that cause adverse effects and thyroid storm
4Ease of operation
If T4 monotherapy is used, then treatment simplicity is maintained, but individual patient needs and varying T3 requirements cannot be met
Solution Approach 1:
The patent segments the thyroid hormone replacement into distinct T3 and T4 components, allowing clinicians to prescribe T4 for baseline therapy and add sustained-release T3 for patients with specific needs (symptomatic hypothyroidism, thyroid cancer suppression), thereby achieving individualized therapy while maintaining treatment simplicity through separate dosing options
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained-release capsules reduce dosing frequency, minimize adverse effects, and improve clinical efficacy by maintaining stable T3 plasma levels, enabling optimal health outcomes and symptom resolution for patients with hypothyroidism.
Implementation Method 1
the hydroxypropyl methylcellulose has 19-30% methoxyl content, 7-12% hydroxypropoxyl content, and 3000-120000 cP apparent viscosity as a 2% solution in water at 20° C.
Implementation Method 2
a sustained release matrix comprising a hydroxypropyl methylcellulose and a filler
Data Source
AI summary
Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.